Alpha Teknova, Inc.
TKNOHealthcare|Drug Manufacturers - Specialty & Generic|US
$7.81
-0.07 (-0.89%)
Tangible Book / Share
$0.91
Cash / Share
$0.31
Financials
Financial Snapshot
Market Cap
$481.9M
Enterprise Value
$502.3M
Revenue (TTM)
$46.0M
Net Income (TTM)
-$16.0M
Cash & Investments
$16.6M
Net Cash
-$10.4M
Free Cash Flow (TTM)
-$6.3M
Operating CF (TTM)
-$5.5M
Debt/Equity
0.45
Cash Runway & Burn Rate
Cash on Hand
$16.6M
Quarterly Burn
$1.4M
Monthly Burn
$455.8K
Est. Runway
~12.1 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $9.7M | $5.1M | $87.5M | $42.2M | $28.5M | $30.4M | $5.9M | $16.6M | |
| Operating Cash Flow | $2.2M | $2.5M | -$9.1M | -$27.4M | -$18.8M | -$12.4M | -$8.6M | -$5.5M | |
| Free Cash Flow | -$477.0K | -$3.0M | -$28.9M | -$55.5M | -$26.7M | -$13.5M | -$9.8M | -$6.3M | |
| Capital Expenditure | -$2.6M | -$5.5M | -$19.9M | -$28.1M | -$7.9M | -$1.1M | -$1.1M | -$814.0K | |
| Financing Cash Flow | $8.6M | -$1.6M | $110.8M | $10.3M | $12.8M | $14.9M | $151.0K | $448.0K |
R&D Spending
R&D (TTM)
$2.3M
R&D Intensity
4.9%
R&D Growth vs Prior
+3.1%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.1M | $31.3M | $36.9M | $41.4M | $36.7M | $37.7M | $40.5M | $46.0M | |
| R&D Expense | $769.0K | $1.5M | $4.3M | $7.7M | $5.6M | $2.8M | $2.2M | $2.3M | |
| R&D % of Revenue | 3.8% | 4.8% | 11.7% | 18.7% | 15.2% | 7.3% | 5.4% | 4.9% | |
| SG&A | $8.6M | $10.4M | $24.2M | $37.4M | $34.8M | $29.5M | $27.1M | $28.3M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.1M | $31.3M | $36.9M | $41.4M | $36.7M | $37.7M | $40.5M | $46.0M | |
| Cost of Revenue | $11.5M | $13.5M | $19.3M | $23.9M | $26.4M | $30.5M | $27.1M | $29.5M | |
| Gross Profit | $8.6M | $17.8M | $17.6M | $17.5M | $10.3M | $7.2M | $13.4M | $16.5M | |
| R&D | $769.0K | $1.5M | $4.3M | $7.7M | $5.6M | $2.8M | $2.2M | $2.3M | |
| SG&A | $8.6M | $10.4M | $24.2M | $37.4M | $34.8M | $29.5M | $27.1M | $28.3M | |
| Operating Income | -$1.9M | $4.7M | -$12.0M | -$49.7M | -$35.6M | -$26.1M | -$17.0M | -$15.0M | |
| Interest Expense | $0.00 | $0.00 | $589.0K | $0.00 | $833.0K | $687.0K | $710.0K | $941.0K | |
| Pretax Income | -$1.8M | $4.7M | -$12.6M | -$49.4M | -$37.1M | -$26.8M | -$17.2M | -$15.9M | |
| Net Income | -$1.3M | $3.6M | -$9.8M | -$47.5M | -$36.8M | -$26.7M | -$17.3M | -$16.0M | |
| EPS (Diluted) | -0.36 | 0.16 | -0.35 | -1.69 | -1.16 | -0.57 | -0.32 | -0.29 | |
| EBITDA | -$233.0K | $6.7M | -$9.2M | -$25.7M | -$25.5M | -$19.6M | -$10.1M | -$10.2M | |
| Shares Out. (M) | 3.64 | 3.98 | 28.01 | 28.08 | 31.82 | 46.75 | 53.48 | 53.69 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.1M | $3.3M | $87.5M | $42.2M | $28.5M | $3.7M | $5.9M | $6.6M | |
| Short-Term Investments | $5.5M | $1.8M | $0.00 | $0.00 | $0.00 | $26.7M | $0.00 | $9.9M | |
| Total Current Assets | $15.4M | $16.4M | $101.2M | $61.1M | $45.7M | $42.8M | $34.5M | $31.8M | |
| Total Assets | $58.5M | $62.9M | $166.5M | $152.3M | $128.6M | $118.8M | $103.6M | $94.7M | |
| Total Current Liabilities | $5.6M | $4.0M | $7.7M | $10.9M | $8.9M | $11.2M | $7.5M | $8.9M | |
| Long-Term Debt | $0.00 | $0.00 | $11.9M | $22.0M | $13.3M | $9.4M | $13.3M | $13.3M | |
| Total Liabilities | $45.6M | $10.5M | $23.3M | $52.4M | $38.6M | $36.4M | $34.8M | $34.9M | |
| Stockholders' Equity | $12.9M | $52.4M | $143.2M | $99.9M | $90.0M | $82.4M | $68.8M | $59.8M | |
| Retained Earnings | -$1.3M | $2.3M | -$7.5M | -$55.0M | -$91.8M | -$118.5M | -$135.8M | -$147.0M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.2M | $2.5M | -$9.1M | -$27.4M | -$18.8M | -$12.4M | -$8.6M | -$5.5M | |
| Capital Expenditure | -$2.6M | -$5.5M | -$19.9M | -$28.1M | -$7.9M | -$1.1M | -$1.1M | -$814.0K | |
| Free Cash Flow | -$477.0K | -$3.0M | -$28.9M | -$55.5M | -$26.7M | -$13.5M | -$9.8M | -$6.3M | |
| Investing Cash Flow | -$8.2M | -$1.7M | -$17.5M | -$28.1M | -$7.7M | -$27.3M | $10.7M | $8.4M | |
| Financing Cash Flow | $8.6M | -$1.6M | $110.8M | $10.3M | $12.8M | $14.9M | $151.0K | $448.0K | |
| Issuance of Stock | $0.00 | $0.00 | $102.7M | $439.0K | $22.5M | $15.1M | $211.0K | $401.0K | |
| Repurchase of Stock | -$19.5M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$847.0K | -$45.0K | $11.9M | $10.1M | -$10.0M | $0.00 | $1.1M | $1.3M | |
| Stock Based Comp. | $0.00 | $300.0K | $1.6M | $3.7M | $4.1M | $3.7M | $3.4M | $2.7M | |
| Net Change in Cash | $2.6M | -$829.0K | $84.2M | -$45.3M | -$13.8M | -$24.8M | $2.2M | $3.4M |
Dilution Tracker
Shares outstanding grew 1244.9% over 5 years — significant dilution
Shares Outstanding
62M
5-Year Share Growth
+1244.9%
Stock Issuance (TTM)
$401.0K
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 3.64 | 3.98 | 28.01 | 28.08 | 31.82 | 46.75 | 53.48 | 53.69 | |
| Change vs Prior % | — | 9.3% | 604.4% | 0.3% | 13.3% | 46.9% | 14.4% | 0.4% | |
| Stock Issuance | $0.00 | $0.00 | $102.7M | $439.0K | $22.5M | $15.1M | $211.0K | $401.0K | |
| Stock Repurchase | -$19.5M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $300.0K | $1.6M | $3.7M | $4.1M | $3.7M | $3.4M | $2.7M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 42.7% | 56.7% | 47.8% | 42.2% | 28.1% | 19.2% | 33.2% | 35.8% | |
| Operating Margin % | -9.2% | 14.9% | -32.5% | -119.9% | -96.9% | -69.3% | -41.9% | -32.7% | |
| Net Margin % | -6.5% | 11.4% | -26.6% | -114.6% | -100.3% | -70.9% | -42.6% | -34.8% | |
| EBITDA Margin % | -1.2% | 21.4% | -24.8% | -62.0% | -69.6% | -51.8% | -25.0% | -22.3% | |
| FCF Margin % | -2.4% | -9.5% | -78.5% | -134.1% | -72.9% | -35.8% | -24.2% | -13.7% | |
| ROE % | -10.1% | 6.8% | -6.8% | -47.5% | -40.9% | -32.5% | -25.1% | -24.9% | |
| ROA % | -2.2% | 5.7% | -5.9% | -31.2% | -28.6% | -22.5% | -16.7% | -16.9% | |
| ROIC % | -2.5% | 6.0% | -5.9% | -33.2% | -29.0% | -23.0% | -17.3% | -17.1% | |
| R&D / Revenue % | 3.8% | 4.8% | 11.7% | 18.7% | 15.2% | 7.3% | 5.4% | 4.9% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 55.8% | 17.9% | 12.3% | -11.4% | 2.9% | 7.4% | |
| Gross Profit | 0.0% | 107.1% | -0.8% | -0.8% | -41.1% | -29.8% | 85.9% | |
| Operating Income | 0.0% | 351.2% | -357.5% | -313.5% | 28.4% | 26.5% | 35.1% | |
| Net Income | 0.0% | 373.6% | -374.6% | -384.2% | 22.5% | 27.3% | 35.5% | |
| EPS (Diluted) | 0.0% | 144.4% | -318.8% | -382.9% | 31.4% | 50.9% | 43.9% | |
| Operating Cash Flow | 0.0% | 15.3% | -462.0% | -202.1% | 31.3% | 34.1% | 30.2% | |
| Free Cash Flow | 0.0% | -520.8% | -877.6% | -91.9% | 51.8% | 49.5% | 27.5% | |
| R&D Expense | 0.0% | 96.0% | 186.1% | 79.4% | -28.0% | -50.4% | -20.4% | |
| SG&A Expense | 0.0% | 21.9% | 131.6% | 54.9% | -7.1% | -15.3% | -8.1% | |
| Total Assets | 0.0% | 7.5% | 164.7% | -8.6% | -15.5% | -7.6% | -12.8% | |
| Book Value / Share | 0.0% | 271.2% | -61.2% | -30.4% | -20.4% | -37.7% | -27.0% | |
| Debt | 0.0% | -100.0% | 0.0% | 256.4% | -28.0% | -0.9% | -49.8% | |
| Diluted Shares | 0.0% | 9.3% | 604.4% | 0.3% | 13.3% | 46.9% | 14.4% |
Valuation
P/E (TTM)At Loss
P/S10.49
10Y Low / Med / High3.18 / 4.52 / 15.55
P/B7.01
10Y Low / Med / High1.32 / 2.96 / 7.04
EV/EBITDAAt Loss
EV/Revenue10.93
10Y Low / Med / High3.07 / 4.32 / 13.50
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$0.91
Cash / Share
$0.31
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -69.44 | 156.25 | -58.51 | -3.34 | -3.22 | -14.65 | -11.88 | -26.47 | |
| P/S Ratio | 4.52 | 3.18 | 15.55 | 3.82 | 3.24 | 10.34 | 5.02 | 10.49 | |
| P/B Ratio | 7.04 | 1.90 | 4.01 | 1.59 | 1.32 | 4.74 | 2.96 | 7.01 | |
| EV/EBITDA | -372.61 | 14.33 | -54.34 | -6.17 | -4.72 | -21.30 | -20.94 | -49.08 | |
| EV/Revenue | 4.32 | 3.07 | 13.50 | 3.83 | 3.29 | 11.04 | 5.24 | 10.93 |
Analyst Estimates & Quality
Altman Z-Score
6.36
Safe
Piotroski F-Score
4
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $46.5M | $53.4M | $62.5M |
| Net Income | -$15.4M | -$12.3M | -$9.5M |
| EPS | $-0.29 | $-0.24 | $-0.18 |
| # Analysts (EPS) | 3 | 3 | 2 |
Revenue Segments
By Product
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Clinical Solutions | $6.8M | $8.4M | $6.7M | $7.1M | $7.7M |
| Lab Essentials | $27.2M | $31.8M | $28.8M | $28.9M | $31.0M |
| Other Product | $1.4M | $1.2M | $1.1M | $1.8M | $1.8M |
| Sample Transport | $1.5M | $6.0K | — | — | — |
By Geography
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Non Us | $1.1M | — | — | — | — |
| U S | $35.8M | — | — | — | — |
| Non-US | — | $1.3M | $1.7M | $1.8M | $2.3M |
| UNITED STATES | — | $40.1M | $35.0M | $35.9M | $38.2M |